达巴万星与对照药物对2015-16年美国及欧洲临床感染中革兰阳性球菌的活性
研究连续收集2015-16年美国及欧洲临床感染中分离的革兰阳性球菌,用微量肉汤稀释法检测达巴万星及对照药物的敏感性。达巴万星对金黄色葡萄球菌、凝固酶阴性葡萄球菌、β溶血链球菌、粪肠球菌、肺炎链球菌和草绿色链球菌均显示活性,作者认为其可能是治疗革兰阳性球菌所致严重感染的候选药物。
要点
- 所有金黄色葡萄球菌(MRSA占36.4%)对达巴万星、替考拉宁和万古霉素敏感。
- 达巴万星对凝固酶阴性葡萄球菌最有效,对β溶血链球菌MIC90为0.03 mg/L。
- 达巴万星对肺炎链球菌和草绿色链球菌最高MIC为0.25 mg/L。
核心结论
- 达巴万星似乎是治疗革兰阳性球菌所致严重感染的可行候选药物。
研究设计与样本
- 连续收集2015-16年美国及欧洲临床感染的革兰阳性球菌,用微量肉汤稀释法检测敏感性。
- 共检测14319株金黄色葡萄球菌、1992株凝固酶阴性葡萄球菌、3269株β溶血链球菌、2071株粪肠球菌、936株屎肠球菌、71株鹑鸡肠球菌/铅黄肠球菌及其他肠球菌、3487株肺炎链球菌和1063株草绿色链球菌。
主要发现
- 所有金黄色葡萄球菌(MRSA占36.4%)对达巴万星、替考拉宁和万古霉素敏感,达帕托霉素和利奈唑胺敏感率>99.9%(按CLSI标准)。
- 达巴万星对金黄色葡萄球菌的MIC结果至少比上述对照药物低16倍。
- 达巴万星对凝固酶阴性葡萄球菌最有效(甲氧西林耐药率CLSI/ EUCAST分别为62.2%/59.6%),其次为达帕托霉素、利奈唑胺和万古霉素。
- 所有万古霉素敏感的粪肠球菌被达巴万星在≤0.25 mg/L(FDA敏感折点)抑制。
- 达巴万星对β溶血链球菌活性很强(MIC90 0.03 mg/L),对肺炎链球菌和草绿色链球菌最有效(最高MIC 0.25 mg/L)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Many infections due to Gram-positive cocci (GPC; staphylococci, streptococci and enterococci) regularly involve prolonged systemic antibiotic use. Dalbavancin has demonstrated activity against GPC isolates and has been approved for the treatment of acute bacterial skin and skin structure infections (ABSSSIs) in adults. OBJECTIVES: To evaluate the activity of dalbavancin against GPC isolated from a variety of infection types in the USA and Europe. METHODS: A total of 14 319 Staphylococcus aureus, 1992 CoNS, 3269 β-haemolytic streptococci (BHS), 2071 Enterococcus faecalis, 936 Enterococcus faecium, 71 Enterococcus gallinarum/casseliflavus and other Enterococcus spp., 3487 Streptococcus pneumoniae and 1063 viridans group streptococci (VGS) causing clinical infections were consecutively collected (2015-16) and tested for susceptibility by broth microdilution methods. RESULTS: All S. aureus (36.4% MRSA) isolates were susceptible to dalbavancin, teicoplanin and vancomycin, while daptomycin and linezolid showed susceptibility rates of >99.9% (according to CLSI criteria). Dalbavancin MIC results were at least 16-fold lower than these comparators against all S. aureus. Dalbavancin was the most potent agent against CoNS [62.2%/59.6% methicillin-resistant (CLSI/EUCAST)], followed by daptomycin, linezolid and vancomycin. All vancomycin-susceptible E. faecalis isolates were inhibited by dalbavancin at ≤0.25 mg/L (FDA susceptible breakpoint). Dalbavancin was very active against BHS (MIC90 0.03 mg/L) and the most active agent against S. pneumoniae and VGS (highest MIC 0.25 mg/L). Ceftriaxone, daptomycin, levofloxacin and vancomycin were also active (93.5%-100.0% susceptible) against VGS, whereas clindamycin, erythromycin, penicillin and tetracycline had lower activity. CONCLUSIONS: Dalbavancin appears to be a viable candidate for treating serious infections caused by GPC.
引用
- Pfaller MA, Mendes RE, Duncan LR, et al. Activity of dalbavancin and comparator agents against Gram-positive cocci from clinical infections in the USA and Europe 2015-16. J Antimicrob Chemother. 2018. PMID: 29982565. doi:10.1093/jac/dky235
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。